Breaking News Instant updates and real-time market news.

NVS

Novartis

$82.46

0.34 (0.41%)

05:20
08/14/18
08/14
05:20
08/14/18
05:20

Novartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk & Compliance Officer

Novartis announced the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive Committee of Novartis. Dr. Moosmayer will join Novartis on December 1, 2018 and will be based in Basel, Switzerland. He succeeds Shannon Thyme Klinger who was recently appointed Group General Counsel. Dr. Moosmayer has been the Chief Compliance Officer of Siemens since January 1, 2014.

  • 25

    Aug

  • 27

    Aug

NVS Novartis
$82.46

0.34 (0.41%)

07/19/18
LEHM
07/19/18
UPGRADE
LEHM
Equal Weight
Novartis upgraded to Equal Weight from Underweight at Barclays
07/19/18
WELS
07/19/18
NO CHANGE
Target $240
WELS
Outperform
Allergan wet AMD data exceed 'unofficial benchmark,' says Wells Fargo
The released efficacy data from Allergan's (AGN) two Phase III trials of its anti-VEGF treatment abicipar in wet age-related macular degeneration looks to have exceeded the "unofficial benchmark set by potential extended-duration competitors," Novartis' (NVS) brolucizumab and Regeneron's (REGN) Eylea, Wells Fargo analyst David Maris tells investors in a research note. The analyst forecasts $125M in sales for abicipar in its first year on the market in 2020 and estimates it will grow to $500M in 2022. Maris keeps an Outperform rating on Allergan with a $240 price target.
08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.

TODAY'S FREE FLY STORIES

HP

Helmerich & Payne

$67.61

0.34 (0.51%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

, SNE

Sony

$56.86

-0.175 (-0.31%)

05:34
09/25/18
09/25
05:34
09/25/18
05:34
Hot Stocks
DHX Media concludes strategic review »

DHX Media (DHXM)…

DHXM

DHX Media

$1.08

-0.11 (-9.24%)

SNE

Sony

$56.86

-0.175 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ASC

Ardmore Shipping

$6.90

-0.05 (-0.72%)

05:33
09/25/18
09/25
05:33
09/25/18
05:33
Upgrade
Ardmore Shipping rating change  »

Ardmore Shipping upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

CENT

Central Garden & Pet

$38.28

-0.95 (-2.42%)

05:30
09/25/18
09/25
05:30
09/25/18
05:30
Initiation
Central Garden & Pet initiated  »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DFIN

Donnelley Financial Solutions

$20.78

0.19 (0.92%)

05:27
09/25/18
09/25
05:27
09/25/18
05:27
Downgrade
Donnelley Financial Solutions rating change  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$207.30

2.25 (1.10%)

05:26
09/25/18
09/25
05:26
09/25/18
05:26
Hot Stocks
Amgen announces approval for Blincyto in Japan »

Amgen announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 17

    Oct

  • 22

    Oct

  • 09

    Nov

SAIC

SAIC

$78.88

-0.59 (-0.74%)

, EGL

Engility

$35.14

-0.12 (-0.34%)

05:23
09/25/18
09/25
05:23
09/25/18
05:23
Upgrade
SAIC, Engility rating change  »

SAIC upgraded to Buy from…

SAIC

SAIC

$78.88

-0.59 (-0.74%)

EGL

Engility

$35.14

-0.12 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLR

Digital Realty

$115.95

-5.055 (-4.18%)

05:19
09/25/18
09/25
05:19
09/25/18
05:19
Syndicate
Digital Realty 8.5M share Secondary priced at $113.00 »

BofA/Merrill and Citi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 04

    Oct

  • 22

    Oct

  • 25

    Sep

SQ

Square

$86.06

0.75 (0.88%)

, FB

Facebook

$165.40

2.5 (1.53%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Recommendations
Square, Facebook, Alphabet, Alphabet Class A, Amazon.com, Netflix analyst commentary  »

Square price target…

SQ

Square

$86.06

0.75 (0.88%)

FB

Facebook

$165.40

2.5 (1.53%)

GOOG

Alphabet

$1,173.38

7.17 (0.61%)

GOOGL

Alphabet Class A

$1,179.78

7.56 (0.64%)

AMZN

Amazon.com

$1,934.50

16.75 (0.87%)

NFLX

Netflix

$369.70

8.71 (2.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 16

    Oct

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 03

    Mar

VIOT

Viomi Technology

$0.00

(0.00%)

05:18
09/25/18
09/25
05:18
09/25/18
05:18
Syndicate
Viomi Technology 11.4M share IPO priced at $9.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

VCTR

Victory Capital

$9.50

0.45 (4.97%)

05:12
09/25/18
09/25
05:12
09/25/18
05:12
Upgrade
Victory Capital rating change  »

Victory Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

  • 10

    Oct

IRET

Investors Real Estate

$5.58

-0.03 (-0.53%)

05:11
09/25/18
09/25
05:11
09/25/18
05:11
Upgrade
Investors Real Estate rating change  »

Investors Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCCI

Heritage-Crystal Clean

$20.40

-0.15 (-0.73%)

05:10
09/25/18
09/25
05:10
09/25/18
05:10
Upgrade
Heritage-Crystal Clean rating change  »

Heritage-Crystal Clean…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 01

    Oct

GHDX

Genomic Health

$70.84

1.65 (2.38%)

, LH

LabCorp

$169.54

-2.46 (-1.43%)

05:09
09/25/18
09/25
05:09
09/25/18
05:09
Recommendations
Genomic Health, LabCorp, Myriad Genetics, Natera, Quest Diagnostics analyst commentary  »

Piper sees early winners…

GHDX

Genomic Health

$70.84

1.65 (2.38%)

LH

LabCorp

$169.54

-2.46 (-1.43%)

MYGN

Myriad Genetics

$46.91

0.64 (1.38%)

NTRA

Natera

$23.83

-0.35 (-1.45%)

DGX

Quest Diagnostics

$107.61

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

  • 27

    Nov

WK

Workiva

$37.20

0.65 (1.78%)

05:08
09/25/18
09/25
05:08
09/25/18
05:08
Upgrade
Workiva rating change  »

Workiva upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CY

Cypress Semiconductor

$15.52

-0.45 (-2.82%)

05:07
09/25/18
09/25
05:07
09/25/18
05:07
Downgrade
Cypress Semiconductor rating change  »

Cypress Semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLAR

Clarus Corporation

$10.45

-0.3 (-2.79%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
Clarus Corporation management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

AMSC

AMSC

$6.33

-0.265 (-4.02%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
AMSC management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

NNBR

NN, Inc.

$15.65

-0.05 (-0.32%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
NN, Inc. to host two day investor day »

Two day investor day to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 06

    Nov

LBTYA

Liberty Global

$28.37

-0.87 (-2.98%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
Liberty Global management to meet with Wolfe Research »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 28

    Sep

TRU

TransUnion

$73.68

-0.62 (-0.83%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
TransUnion management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 21

    Oct

  • 23

    Oct

TSLX

TPG Specialty Lending

$20.56

-0.15 (-0.72%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
TPG Specialty Lending management to meet with JMP Securities »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

THR

Thermon Group

$25.98

-0.14 (-0.54%)

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
Thermon Group management to meet with William Blair »

Group luncheon with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

04:55
09/25/18
09/25
04:55
09/25/18
04:55
General news
Richmond Fed Manufacturing Index Level to be reported at 10:00 »

September Richmond Fed…

04:55
09/25/18
09/25
04:55
09/25/18
04:55
Conference/Events
AdvaMed to hold a conference »

MedTech Conference will…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.